ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Travel-associated hepatitis A in Europe, 2009 to 2015
Beauté, J., Westrell, T., Schmid, D., Müller, L., Epstein, J., Kontio, M., Couturier, E., Faber, M., Mellou, K., Borg, M.-L., Friesema, I., Vold, L., Severi, E.
Accessibility and acceptability of infectious disease interventions among migrants in the eu/eea: A cerqual systematic review
Driedger, M., Mayhew, A., Welch, V., Agbata, E., Gruner, D., Greenaway, C., Noori, T., Sandu, M., Sangou, T., Mathew, C., Kaur, H., Pareek, M., Pottie, K.
The effectiveness and cost-effectiveness of screening for and vaccination against hepatitis B virus among migrants in the EU/EEA: A systematic review
Myran, D.T., Morton, R., Biggs, B.-A., Veldhuijzen, I., Castelli, F., Tran, A., Staub, L.P., Agbata, E., Rahman, P., Pareek, M., Noori, T., Pottie, K.
Hepatitis A Seroprevalence in a population of immigrants at a French vaccination centreArchived
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
Universal screening for hepatitis B among pregnant women led to 96% vaccination coverage among newborns of HBsAg positive mothers in DenmarkArchived
Universal screening of pregnant women is feasible and has led to immunisation in nearly all identified cases in Denmark. As a consequence of the study the National Board of Health has made universal HBsAg screening of pregnant women permanent in the country.